Trump administration nixes plan to cover anti-obesity drugs through Medicare
Proponents of coverage argued treating obesity can reduce longer-term costs by cutting down on heart attacks and other health ...
Trump rejects plan for Medicare to cover weight loss drugs
President Donald Trump’s team is rejecting former President Biden's plan to cover weight loss drugs like Wegovy and Zepbound for older Americans through Medicare. The Centers for Medicare and Medicaid ...
Senate Overwhelmingly Rejects Sanders’s Resolutions to Halt Trump Administration’s Israel Aid
Sanders hoped to halt the Trump administration’s planned $8.8 billion sale of bombs and other weaponry to Israel as it ...
Novo Holdings nearly doubles earnings as Wegovy swells coffers
Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk , nearly doubled annual income and investment ...
Wegovy sees Novo Holdings double income and returns in 2024
Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk, nearly doubled annual income and investment ...
MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company developing breakthrough therapeutics for neurologic and neuropsychiatric disorders, today announced the enrollment of ...
Alternative version of Ozempic, Wegovy may not be available much longer
Affordable and alternative versions of popular weigh loss drugs, like Ozempic and Wegovy, may no longer be available.